Richter: Schizophrenia drug does well in trial
Hungarian drugmaker Gedeon Richter and Dublin-based partner Actavis today announced positive results from a "phase III trial" evaluating the effectiveness and safety of their new drug cariprazine in the prevention of relapse in patients with schizophrenia.
The test reportedly involved 101 patients receiving cariprazine and 99 receiving a placebo. There were 25 relapses (24.8%) in the cariprazine group versus 47 relapses (47.5%) in the placebo group, the drug companies said.
“We are encouraged by the positive top line results shown in this study, which are considered a further milestone in the process of making this promising treatment option available for patients suffering from schizophrenia,” said Dr. István Greiner, Research Director of Gedeon Richter.
The U.S. Food and Drug Administration (FDA) acknowledged the receipt of the two companies’ new drug application resubmission for cariprazine, according to an announcement earlier this month.
One of the blue chips on the Budapest Stock Exchange, Gedeon Richter has been concerned about reduced profits due to the economic troubles in Russia, where the firm has been earning nearly one quarter of its revenue.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.